Diffuse low-grade and intermediate-grade gliomas (together known as lower-grade gliomas, WHO grade II and III) 3 4 develop in the supporting glial cells of brain and are the most common types of primary brain tumor. Despite a 3 5 better prognosis for lower-grade gliomas, 70% of patients undergo high-grade transformation within 10 years, 3 6 stressing the importance of better prognosis. Long non-coding RNAs (lncRNAs) are gaining attention as potential 3 7 biomarkers for cancer diagnosis and prognosis. We have developed a computational model, UVA8, for prognosis of 3 8 lower-grade gliomas by combining lncRNA expression, Cox regression and L1-LASSO penalization. The model 3 9 was trained on a subset of patients in TCGA. Patients in TCGA, as well as a completely independent validation set 4 0 (CGGA) could be dichotomized based on their risk score, a linear combination of the level of each prognostic 4 1 lncRNA weighted by its multivariable cox regression coefficient. UVA8 is an independent predictor of survival and 4 2 outperforms standard epidemiological approaches and previous published lncRNA-based predictors as a survival 4 3 model. Guilt-by-association studies of the lncRNAs in UVA8, all of which predict good outcome, suggest they have 4 4 a role in suppressing interferon stimulated response and epithelial to mesenchymal transition. The expression levels 4 5
1 0 0 more robust machine learning approach is required to find genes as prognostic signature from a multi-dimensional In the present study, we develop an lncRNA-based prognostic signature in combination with Cox 1 0 5 regression and L1-LASSO regularization to model survival of grade II and grade III glioma patients. This is the first 1 0 6 study that combined Cox and Lasso regularization to select lncRNAs that can predict survival in glioma patients. After controlling for covariates associated with glioma survival (age, grade, IDH1 mutation status), we selected 8 1 0 8 lncRNAs UVA8, to calculate a risk-score, which successfully divides patients into high-risk and low-risk groups in 1 0 9 both TCGA (461 patients) and CGGA (274 patients) dataset. The risk score calculated by these 8 lncRNAs is an 1 1 0 independent and better prognostic marker for grade II and grade III glioma patient survival. The guilt-by-association 1 1 1 analysis of lncRNAs in UVA8 indicated their role in suppressing interferon signaling pathway and epithelial to 1 1 2 5 mesenchymal transition. Besides their use as a biomarker, these lncRNAs need to be studied in detail to determine 1 1 3 how they affect patient outcome. The most recent version of Gencode (GENCODE v 26) GTF file available at the time of this study was used for the 1 2 7 gene quantification [27] . Gene abundance in FPKM was obtained for 58219 genes with 15787 genes annotated as expression of 1 FPKM in 512 LGG patients were finally considered for the survival model. The gene-expression data for lncRNAs was Z-score transformed to avoid systematic error across different experiments. We first randomly selected 60% of TCGA patients for training set and remaining 40% of TCGA effect on survival (Figure S1) , we assessed the prognostic potential of each lncRNA by multivariate Cox-regression 1 3 5 controlling the effects from these other variables. We used FDR corrected p-value cutoff of 0.05 obtained after log- Coefficients are median cox-coefficient (after lasso selection and multivariate cox-regression) for each of the 8 1 4 9 lncRNAs from the successful models (models which can stratify patients in testing set). We developed an lncRNA based survival model for gliomas through the following steps ( Figure 1 ). 3) LncRNAs significantly associated with survival after likelihood ratio test (FDR p < 0.05) were retained 1 6 5 for selecting lncRNAs by lasso regularization. calculate risk score and stratify patients into two groups in testing set. Steps 1-6 were repeated 100 times to obtain up to 100 different lncRNA subsets (models). Only those models that 1 7 5 separated patients in the testing set such that those with low-risk score had significantly better survival than those 1 7 6
with high-risk score were considered as successful models and retained. The result obtained from one such survival model is shown in FigureS2. In ~20% of the trials the multivariate cox- survival (NA in Figure 2A) . The remaining 80% of the survival models contained different numbers of lncRNAs (x-1 8 0 axis of Figure 2A ) that significantly stratify patients into low and high-risk groups in training set (Figure 2A) .
Among these 80% of survival models, 86% also significantly separated patients into high-risk and low-risk in the instead of Lasso, for regularization and lncRNA selection (Figure S3C) suggesting the prognostic importance of 1 9 0 these 8 lncRNAs in gliomas. For brevity, this set of 8 lncRNA as a prognostic signature of gliomas will be referred 1 9 1 to as UVA8 in the manuscript. We assessed the predictive power of UVA8 by comparing overall survival of low and high risk patients in the entire 1 9 4
TCGA dataset stratified based on median risk score obtained by UVA8 (risk score calculation discussed in 1 9 5 methods). Patients in the low-risk group showed longer overall survival than the high-risk group in TCGA dataset dataset range from -4 to 4 with median risk score of -0.023 (Figure 3B, top panel) . Moreover, there are more 1 9 8 patients alive in the low risk group than in the high-risk group (Figure 3B, middle panel) . Interestingly, expression Since, 32% of patients in CGGA are in grade IV, the difference in overall survival could be due to over- III) were separately examined we found significantly longer survival for low-risk versus high-risk patients ( Figure   2 1 0 S4A). UVA8 fails to cluster grade IV patients from CGGA into two distinct groups highlighting the specificity of 2 1 1 signature for lower-grade gliomas (Figure S4B) . Lower grade gliomas have poorer outcomes in older patients, in tumors of higher grade and tumors with wild type 2 1 4 IDH1 status (Figure S1) . Interestingly, the risk score derived from UVA8 is higher in patients older than 40 years, 2 1 5 patients in grade III vs grade II and patients harboring wild-type IDH1 gene (Figure S5) . It was therefore important 2 1 6
to determine whether UVA8 derived risk score is an independent predictor of survival. We divided the patients into 2 1 7 younger (Age < 40) and older (Age >= 40) groups and found that risk-score can still stratify the patients into low-2 1 8 risk and high risk in both groups (Figure 4A) . Similarly, UVA8 based risk score can still separate the patients into 2 1 9 low and high-risk groups in grade II or grade III gliomas (Figure 4B) . Although, IDH mutation status is a widely 2 2 0 used prognostic and predictive biomarker, the UVA8 based risk score can also separate patients into two risk groups 2 2 1 in patients presorted based on IDH mutation status ( Figure 4C ). UVA8 derived risk score can also stratify patients 2 2 2 into two risk groups among male and female patients (Figure 4D ).
2 2 3
Conversely we tested whether these standard clinically used parameters, age, gender, grade and IDH mutation status, 2 2 4 continue to independently stratify patients even after they have been presorted into two groups by UVA8 risk score 2 2 5
( Figure S6) . In patients with high UVA8 risk score, age, grade and IDH mutations status can further separate the clinical factors could further stratify patients into two different survival groups with a pvalue<0.05 (Figure S6 ).
8
Consistent with the previous observation (Figure S1) , gender is ineffective in stratifying patients into two categories 2 2 9
within patients with high-or low-risk score. We assessed the accuracy of UVA8 in prediction of survival by comparing its time-dependent area under curve 2 3 2 (AUC) with other clinical characteristics. For each prognostic factor (e.g. UVA8, IDH status etc.) we varied the cut- corresponding true positive rate for five-year survival was calculated (Figure 5A) . Comparing the Area-under the the AUC plotted for each predictor (Figure 5B) . UVA8 can predict survival better for all durations, particularly at 2 3 8 1 0 the very early years after diagnosis when the prediction is worse for most of the predictors. Since, gender is not 2 3 9 associated with glioma patients' survival (Figure S1) , the prediction of outcome was no better than random guess 2 4 0 (AUC = 0.5) ( Figure 5A and 5B) . We employed Cox multivariable probability hazard model to identify the impact 2 4 1 of UVA8 and different clinicopathological characteristics in estimating hazard (Figure 5C ). UVA8 is most 2 4 2 significantly correlated with the survival information (p = 1.4e-07) and shows highest hazard ratio (HR = 4), lncRNAs individually and combined as risk score is tabulated in Supplementary Table S1 . The UVA8 Risk score Supplementary Table S1 is different from that in Figure 5C because in the former the hazard ratio is calculated 2 5 0 with the risk score as a continuous variable.
5 1
We then sought to compare the performance of UVA8 based survival model with published lncRNA based survival 2 5 2 models by calculating Cindex (as discussed in Methods) for TCGA dataset for each of the models. We first 2 5 3 calculated risk score for each patient by considering the expression level of the prognostic lncRNAs in each model weighted by their estimated regression coefficients retrieved from the respective studies (Supplementary Table   2 5 5 S2). The patients were ordered based on their actual survival at a given time after diagnosis and based on their risk 2 5 6 score in each model. The concordance of the two orders is measured in pairwise comparisons of the patients to 2 5 7 calculate a single time-dependent concordance index for the model that is being evaluated. UVA8 outperforms all 2 5 8 existing lncRNA based survival models at different times after diagnosis (Figure 5D ). As expected, prognostic 2 5 9 signatures that were specific to GBMs (Zhang6_2013 and Zhou6_2017) show poor concordance index when used to
